ASMB — ASSEMBLY BIOSCIENCES, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1426800 ·
Last close
$28.75
Market Cap
$456.91M
52W High
$32.46
52W Low
$25.76
ADV30
157,311
Next earnings
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 8,213,000 -11,370,000 -9,079,000 235,508,000 31,120,000 36,898,000
Dec 2025 42,469,000 19,799,000 22,090,000 257,590,000 58,450,000 50,839,000
Sep 2025 10,789,000 -10,883,000 -9,196,000 239,997,000 22,534,000 57,302,000
Jun 2025 9,626,000 -11,093,000 -10,198,000 80,780,000 24,006,000 62,680,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-41,093,000
Investing CF
$-113,468,000
Financing CF
$174,667,000
CapEx
$-24,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-4.73
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-832,047,000
Inventory
Receivables
$974,000
ST Investments
$189,656,000
EBIT TTM
$-12,118,000
Pretax Income TTM
$-6,122,000
Interest Exp TTM
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$71,097,000
EBITDA
$-13,418,750
Free Cash Flow
Enterprise Value
$232,795,152
Total Cash
$226,600,992
Total Debt
$2,491,000
Shares Out
15,892,608
Trailing EPS
$0.08
Book Value
$12.50
ROE
-5.7%
ROA
-5.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 72,303,000 -12,118,000 -6,122,000 257,590,000 50,839,000 -41,093,000
Dec 2024 28,520,000 -45,420,000 -40,177,000 119,168,000 85,809,000 -51,117,000
Dec 2023 7,163,000 -64,646,000 -61,228,000 136,823,000 95,726,000 22,743,000
Dec 2022 0 -94,114,000 -93,092,000 101,794,000 19,130,000 -84,463,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.33

Peers — same industry

TickerNameMarket CapLastDaily %
OVID Ovid Therapeutics Inc. $457.27M $2.45
CYDY CytoDyn Inc. $457.62M $0.34
KMDA KAMADA LTD $458.60M $7.95
FULC Fulcrum Therapeutics, Inc. $450.44M $6.76
FBRX Forte Biosciences, Inc. $449.31M $21.94

News headlines (Yahoo Finance, 1h cache)

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-05-26 20:05 · Yahoo
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
2026-05-22 11:05 · Yahoo
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
2026-05-22 11:00 · Yahoo
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
2026-05-14 11:05 · Yahoo
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts
2026-05-13 11:29 · Yahoo
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
2026-05-13 06:00 · Yahoo
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
2026-05-11 12:00 · Yahoo
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
2026-05-11 11:12 · Yahoo
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 21:15 · Yahoo
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-07 20:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.